InBody Co.,Ltd (041830.KQ)
KRW 21950.0
(-1.13%)
KRW 21950.0
(-1.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.2 Billion KRW | -6.89% |
| 2022 | -15.16 Billion KRW | -3.17% |
| 2021 | -14.69 Billion KRW | -20.59% |
| 2020 | -12.18 Billion KRW | -2.76% |
| 2019 | -11.85 Billion KRW | -23.18% |
| 2018 | -9.62 Billion KRW | 16.59% |
| 2017 | -11.54 Billion KRW | -8.98% |
| 2016 | -10.59 Billion KRW | -87.56% |
| 2015 | -5.64 Billion KRW | -19.59% |
| 2014 | -4.72 Billion KRW | -7.32% |
| 2013 | -4.39 Billion KRW | 3.64% |
| 2012 | -4.56 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -16.96 Billion KRW | 17.01% |
| 2024 Q1 | -20.44 Billion KRW | -26.17% |
| 2023 Q4 | -16.2 Billion KRW | 4.9% |
| 2023 FY | -16.2 Billion KRW | -6.89% |
| 2023 Q1 | -15.9 Billion KRW | -4.92% |
| 2023 Q2 | -14.76 Billion KRW | 7.16% |
| 2023 Q3 | -17.04 Billion KRW | -15.4% |
| 2022 FY | -15.16 Billion KRW | -3.17% |
| 2022 Q4 | -15.16 Billion KRW | 7.85% |
| 2022 Q3 | -16.45 Billion KRW | -5.45% |
| 2022 Q2 | -15.6 Billion KRW | -12.4% |
| 2022 Q1 | -13.88 Billion KRW | 5.54% |
| 2021 Q1 | -14.26 Billion KRW | -0.64% |
| 2021 Q3 | -10.62 Billion KRW | 13.2% |
| 2021 Q4 | -14.69 Billion KRW | -38.28% |
| 2021 Q2 | -12.24 Billion KRW | 14.16% |
| 2021 FY | -14.69 Billion KRW | -20.59% |
| 2020 Q2 | -13.61 Billion KRW | -10.68% |
| 2020 FY | -12.18 Billion KRW | -2.76% |
| 2020 Q3 | -15.45 Billion KRW | -13.56% |
| 2020 Q1 | -12.29 Billion KRW | -3.69% |
| 2020 Q4 | -14.17 Billion KRW | 8.32% |
| 2019 Q4 | -11.85 Billion KRW | 24.13% |
| 2019 FY | -11.85 Billion KRW | -23.18% |
| 2019 Q3 | -15.62 Billion KRW | 6.98% |
| 2019 Q2 | -16.8 Billion KRW | -23.52% |
| 2019 Q1 | -13.6 Billion KRW | -41.29% |
| 2018 Q1 | -8.51 Billion KRW | 24.24% |
| 2018 Q4 | -9.62 Billion KRW | -144.66% |
| 2018 FY | -9.62 Billion KRW | 16.59% |
| 2018 Q2 | 6.09 Billion KRW | 171.55% |
| 2018 Q3 | -3.93 Billion KRW | -164.57% |
| 2017 FY | -11.54 Billion KRW | -8.98% |
| 2017 Q4 | -11.24 Billion KRW | 5.23% |
| 2017 Q3 | -11.86 Billion KRW | -20.69% |
| 2017 Q1 | -8.48 Billion KRW | 17.55% |
| 2017 Q2 | -9.82 Billion KRW | -15.84% |
| 2016 Q4 | -10.29 Billion KRW | -58.02% |
| 2016 FY | -10.59 Billion KRW | -87.56% |
| 2016 Q2 | -8.19 Billion KRW | -35.42% |
| 2016 Q1 | -6.04 Billion KRW | -7.11% |
| 2016 Q3 | -6.51 Billion KRW | 20.48% |
| 2015 Q3 | -6 Billion KRW | -8.61% |
| 2015 Q1 | -4.4 Billion KRW | 6.79% |
| 2015 FY | -5.64 Billion KRW | -19.59% |
| 2015 Q4 | -5.64 Billion KRW | 5.99% |
| 2015 Q2 | -5.53 Billion KRW | -25.66% |
| 2014 Q3 | -3.88 Billion KRW | 7.87% |
| 2014 Q4 | -4.72 Billion KRW | -21.68% |
| 2014 Q2 | -4.21 Billion KRW | 27.29% |
| 2014 Q1 | -5.79 Billion KRW | -31.66% |
| 2014 FY | -4.72 Billion KRW | -7.32% |
| 2013 Q2 | -4.59 Billion KRW | -22.07% |
| 2013 Q4 | -4.39 Billion KRW | 11.97% |
| 2013 FY | -4.39 Billion KRW | 3.64% |
| 2013 Q1 | -3.76 Billion KRW | 17.53% |
| 2013 Q3 | -4.99 Billion KRW | -8.73% |
| 2012 Q3 | -1.4 Billion KRW | 0.0% |
| 2012 FY | -4.56 Billion KRW | 0.0% |
| 2012 Q4 | -4.56 Billion KRW | -224.5% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | -108.91 Billion KRW | 85.121% |
| Curexo Inc. | -15.03 Billion KRW | -7.804% |
| Seegene, Inc. | -48.57 Billion KRW | 66.639% |
| i-SENS, Inc. | 98.45 Billion KRW | 116.46% |
| Ray Co., Ltd. | 67.09 Billion KRW | 124.153% |
| Gencurix Inc. | 15.02 Billion KRW | 207.857% |
| Sugentech Inc. | -6.95 Billion KRW | -133.126% |
| L&C Bio Co., Ltd | 67.18 Billion KRW | 124.121% |